Enzyme kinetics
Study of biochemical reaction rates catalysed by an enzyme
Follow Enzyme kinetics on Notably News to receive short updates to your email — rarely!
We include updates on Prednisone, Omeprazole, Modafinil, Dexamethasone, Capsaicin, Tobacco, Phenobarbital, Methylprednisolone, Haloperidol, Prednisolone, Topiramate, Hypericum perforatum, Carbamazepine, Pentobarbital, Metamizole, Hydrocortisone ... and more.
| 2022 |
Lumacaftor/ivacaftor
FDA further expanded approval of lumacaftor/ivacaftor to include children aged 1-2 years old.
|
| 2019 |
Lumacaftor/ivacaftor
NHS Scotland and NHS England both negotiated and struck deals with Vertex Pharmaceuticals regarding the drug.
|
| November 2019 |
Lumacaftor/ivacaftor
Pricing was agreed upon in the United Kingdom, with expectations of the drug being covered by the national healthcare system in November of this year.
|
| 2018 |
Lumacaftor/ivacaftor
FDA expanded approval of lumacaftor/ivacaftor to include children aged 2-5 years old.
|
| October 2017 |
Lumacaftor/ivacaftor
The Dutch Minister of Health initially announced that the drug would not be admitted to the public health insurance package due to its high cost of 170,000 euros per patient per year.
|
| October 25 2017 |
Lumacaftor/ivacaftor
The Dutch Minister of Health announced an agreement with Vertex Pharmaceuticals, resulting in the drug being admitted to the Dutch public health insurance package, with the price negotiation details kept confidential.
|
| 2016 |
Lumacaftor/ivacaftor
Lumacaftor/ivacaftor received medical approval in Canada, expanding its availability for cystic fibrosis patients with the specific genetic mutation.
|
| 2015 |
Lumacaftor/ivacaftor
Lumacaftor/ivacaftor (Orkambi) was approved for medical use in the United States, providing a treatment option for people with cystic fibrosis who have two copies of the F508del mutation.
|
| August 2015 |
Lumacaftor/ivacaftor
In Denmark, the estimated annual cost of the drug was calculated at 2 million Danish krones (approximately 270,000 euros) per person.
|
| July 2015 |
Lumacaftor/ivacaftor
FDA approved lumacaftor/ivacaftor under breakthrough therapy status and priority review for treating cystic fibrosis in adults and pre-teens.
|
This contents of the box above is based on material from the Wikipedia article Lumacaftor/ivacaftor, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.